Scarica l'app Stockscreener
12.52
3.22%
0.39
Dopo l'orario di chiusura:
12.40
-0.12
-0.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Viatris Inc Borsa (VTRS) Ultime notizie
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn? - Insider Monkey
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology - The Malaysian Reserve
Cenerimod shows promise in SLE trial, Viatris reports - Investing.com
Viatris announces publication of CARE study results - TipRanks
Viatris's Lupus Drug Cenerimod Shows Powerful Disease Activity Improvement in Phase 2b Clinical Trial - StockTitan
(VTRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Lidocaine Patches Market to See Booming Growth 2024-2031 | Endo - openPR
Viatris's SWOT analysis: generic drug maker's stock faces growth hurdles - Investing.com
Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference - The Eastern Progress Online
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence and AI-Powered Market TransformationTechnavio - The Malaysian Reserve
Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers - The Eastern Progress Online
Catecholamines Drugs Market: Emerging Technology and Investor - openPR
Viatris Reports Third Quarter Financial Results for 2024 - Longview News-Journal
Viatris shareholders approve stock plan amendment, reject executive compensation By Investing.com - Investing.com Canada
Viatris shareholders approve stock plan amendment, reject executive compensation - Investing.com
(VTRS) Investment Analysis - Stock Traders Daily
Viatris Elects Directors and Amends Stock Plan at Meeting - Nasdaq
Generic Pharmaceuticals Market Future Business Opportunities - openPR
Coccidioidomycosis Drugs Market to Reach US$ 634.3 Million by 2034, Expanding at a CAGR of 4.9% | Fact.MR Report - GlobeNewswire Inc.
Anti Depression Drugs Market is expected to reach US$ 22.10 - openPR
Naloxone Market Growth in Future Scope 2024-2031 | Akorn, Inc, - openPR
Viatris Says Goodbye To Another Generics Asset - Citeline
2 Generic Drug Stocks Ready to Surge in 2025 - MarketBeat
Hypopituitarism Treatment Market to Witness Huge Growth - openPR
Hypovolemic Shock Market Growth Analysis: Industry Expansion - openPR
UK CMA fines Viatris for breaching order during Theramex deal probe - World Pharmaceutical Frontiers
Viatris fined in Morocco over merger notification, sources say - MSN
Vitaris fined in Morocco over merger notification, sources say - MSN
Morocco fines Viatris 7.58 million dirhams over Mylan-Pfizer merger - MSN
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe - Reuters.com
Viatris Fined £1.5M For Failing To Comply With CMA Order - Law360
Viatris fined £1.5M for failure to comply with CMA order - MSN
Viatris fined £1.5M for failure to comply with CMA order (NASDAQ:VTRS) - Seeking Alpha
UK watchdog fines Viatris $1.9 million over rule breach in Theramex probe - Marketscreener.com
Viatris Fined £1.5M for CMA Order Breach - Mirage News
Viatris fined £1.5m for failure to comply with CMA order - GOV.UK
Ampicillin Market to Continue Impressive Measured Growth - openPR
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com
Australia Passes Strict Social Media Ban for Under-16s - PYMNTS.com
Viatris fined in Morocco over merger notification, sources say By Reuters - Investing.com
0.34%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):